Nervous System News and Research

Latest Nervous System News and Research

Scientists identify potential new method for treating sleeping sickness

Scientists have identified a potential new approach to treat human African trypanosomiasis (HAT), commonly known as sleeping sickness, which afflicts "tens of thousands of people in sub-Saharan Africa" annually, IRIN reports. By targeting an enzyme the sleeping sickness parasite needs in order to survive, researchers say they can kill it without causing harm to the patient (4/1).

2 Apr 2010

New development in treatment of African Sleeping Sickness

African sleeping sickness or Human African Typanosomiasis is a potentially fatal disease affecting 50 to 70 thousand Africans each year. Carried by the bite tsetse fly this fatal disease is actually caused by a tiny parasite that attacks the nervous system, brain, spinal column resulting in mental confusion and finally death.

1 Apr 2010

Catalyst Pharmaceutical Partners reports net loss of $7.24M for fourth-quarter 2009

Catalyst Pharmaceutical Partners, Inc., a biopharmaceutical company that acquires, in-licenses, develops and commercializes prescription drugs for the treatment of diseases of the central nervous system, today reported financial results for the fourth quarter and year ended December 31, 2009.

1 Apr 2010

IGEN Networks signs MOU with Bio Business Development

IGEN Networks Corp. is pleased to announce that it has signed a memorandum of understanding with Bio Business Development Corp. International, Inc. to negotiate the acquisition of the exclusive global distribution rights to the patented lateral-flow diagnostic testing platform technology for rapid detection of the infectious prion protein diseases.

1 Apr 2010

Positive results from Phase 2 clinical trial of OMS103HP

Omeros Corporation today announced that a Phase 2 clinical trial of OMS103HP, its PharmacoSurgery™ product candidate for arthroscopy, demonstrated that patients treated with OMS103HP during arthroscopic knee meniscectomy surgery achieved statistically significant clinical benefits.

1 Apr 2010

Orexigen Therapeutics announces submission of Contrave NDA for treatment of obesity

Orexigen® Therapeutics, Inc. announced that the Company has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Contrave® (naltrexone SR/bupropion SR), its investigational drug for the treatment of obesity. The NDA is based on a substantial body of evidence gathered through the Contrave Obesity Research (COR) clinical program, which included over 4,500 patients.

1 Apr 2010

Recipients of Pfizer Canada's third Neuropathic Pain Research Awards Competition announced

Pfizer Canada is pleased to announce the recipients of its third Neuropathic Pain Research Awards Competition, which aims to fund and support Canadian innovation within independent neuropathic pain research in the areas of basic biomedical, clinical and health sciences.

31 Mar 2010

Nation's emergency physicians warn parents about dangers of prescription drug abuse

The nation's emergency physicians are issuing a strong warning to parents about the dangers of prescription drug abuse, which are now the second most abused drugs, after marijuana. Nearly three-quarters of a million people (741,425) needed emergency care in 2006 because of prescription drug abuse.

31 Mar 2010

$Notch pathway could aid treatment of osteoporosis, fractures and arthritis$

Notch pathway could aid treatment of osteoporosis, fractures and arthritis

Scientists seeking new ways to fight maladies ranging from arthritis and osteoporosis to broken bones that won't heal have cleared a formidable hurdle, pinpointing and controlling a key molecular player to keep stem cells in a sort of extended infancy.

31 Mar 2010

AAN awards 2010 Dreifuss-Penry Epilepsy Award to Vanderbilt University School of Medicine researcher

The American Academy of Neurology (AAN) is awarding the 2010 Dreifuss-Penry Epilepsy Award to Martin J. Gallagher MD, PhD, with Vanderbilt University School of Medicine. Gallagher will receive the award during the AAN's 62nd Annual Meeting in Toronto, held April 10 through April 17, 2010.

31 Mar 2010

AAN awards Cedars-Sinai researcher 2010 Sheila Essey Award for ALS research

The American Academy of Neurology (AAN) is awarding the 2010 Sheila Essey Award-An Award for ALS Research to Clive Svendsen, PhD, with the Cedars-Sinai Regenerative Medicine Institute in Los Angeles, CA. Svendsen will receive the award during the AAN's 62nd Annual Meeting in Toronto, held April 10 through April 17, 2010.

31 Mar 2010

2010 John Dystel Prize for Multiple Sclerosis Research awarded to Yale University researcher

The American Academy of Neurology is awarding the 2010 John Dystel Prize for Multiple Sclerosis Research to David A. Hafler, MD, with Yale University. Hafler will receive the award during the AAN's 62nd Annual Meeting in Toronto, held April 10 through April 17, 2010.

31 Mar 2010

NeurOp and Bristol-Myers Squibb announce drug discovery collaboration

NeurOp Corporation today announced a collaboration with Bristol-Myers Squibb Company (NYSE: BMY) focused upon the development of NeurOp's proprietary small molecules for use in the treatment of major depression and other central nervous system disorders.

31 Mar 2010

Top neurologists to receive 2010 AAN Alliance Awards

The American Academy of Neurology will recognize the outstanding achievements of researchers in neurology during the AAN's 62nd Annual Meeting in Toronto, April 10 through 17, 2010, the world's largest gathering of neurologists with more than 2,000 presentations on the latest advances in neurologic research.

31 Mar 2010

QRxPharma initiates Phase 1 trial for evaluating PK profiles of morphine, oxycodone CR formulations

QRxPharma announced today initiation of the Company's first Phase 1 trial to evaluate the pharmacokinetic (PK) profiles of experimental controlled-release (CR) morphine and oxycodone formulations that will be incorporated into MoxDuo®CR. MoxDuo®CR contains a fixed 3:2 morphine:oxycodone combination and is intended to be dosed twice daily in patients experiencing chronic pain, an approximately US$7 billion dollar market worldwide.

31 Mar 2010

Two Phase I studies of Stedivaze demonstrate safety in patients with asthma and COPD

Clinical Data, Inc., today announced results from two Phase I studies of Stedivaze™ (apadenoson), which demonstrated that Stedivaze was safe and well tolerated in patients with asthma and chronic obstructive pulmonary disease (COPD). Stedivaze is a potent and highly selective agonist of the adenosine A2A receptor subtype in development as a pharmacologic stress agent for myocardial perfusion imaging (MPI).

30 Mar 2010

Insight into scorpion venom may help understand diseases like pancreatitis

A Brazilian scorpion has provided researchers at North Carolina State University and East Carolina University insight into venom's effects on the ability of certain cells to release critical components. The findings may prove useful in understanding diseases like pancreatitis or in targeted drug delivery.

30 Mar 2010

New DNA test to detect Lyme disease spirochete infection

Many of the more than 30,000 people a year in the United States with suspected cases of Lyme disease spirochete (bacterial) infection can now take a DNA test developed by a Connecticut scientist/physician and his team that can quickly determine if they test positive for Lyme spirochetes in their blood.

30 Mar 2010

Higher levels of CRP associated with brain changes: Study

New research shows that a high level of C-reactive protein, a marker for inflammation in the blood, is associated with brain changes that are linked to problems with executive thinking skills. The study is published in the March 30, 2010, issue of Neurology®, the medical journal of the American Academy of Neurology.

30 Mar 2010

LCT receives approval for New Zealand Phase II human trial of DIABECELL

Living Cell Technologies Limited, a global company pioneering the development of a cell implant to treat diabetes, today announced that it has received approval to advance to the next phase of its New Zealand Phase II human clinical trial with its groundbreaking DIABECELL®. The approval follows a positive assessment from the New Zealand Data Safety and Monitoring Board of the first four patients to receive its DIABACELL® implants.

30 Mar 2010

Nervous System News and Research

Latest Nervous System News and Research

Scientists identify potential new method for treating sleeping sickness

New development in treatment of African Sleeping Sickness

Catalyst Pharmaceutical Partners reports net loss of $7.24M for fourth-quarter 2009

IGEN Networks signs MOU with Bio Business Development

Positive results from Phase 2 clinical trial of OMS103HP

Orexigen Therapeutics announces submission of Contrave NDA for treatment of obesity

Recipients of Pfizer Canada's third Neuropathic Pain Research Awards Competition announced

Nation's emergency physicians warn parents about dangers of prescription drug abuse

Notch pathway could aid treatment of osteoporosis, fractures and arthritis

AAN awards 2010 Dreifuss-Penry Epilepsy Award to Vanderbilt University School of Medicine researcher

AAN awards Cedars-Sinai researcher 2010 Sheila Essey Award for ALS research

2010 John Dystel Prize for Multiple Sclerosis Research awarded to Yale University researcher

NeurOp and Bristol-Myers Squibb announce drug discovery collaboration

Top neurologists to receive 2010 AAN Alliance Awards

QRxPharma initiates Phase 1 trial for evaluating PK profiles of morphine, oxycodone CR formulations

Two Phase I studies of Stedivaze demonstrate safety in patients with asthma and COPD

Insight into scorpion venom may help understand diseases like pancreatitis

New DNA test to detect Lyme disease spirochete infection

Higher levels of CRP associated with brain changes: Study

LCT receives approval for New Zealand Phase II human trial of DIABECELL

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Nervous System News and Research

Latest Nervous System News and Research

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Newsletters you may be interested in